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aortic annulus with respect to sizing, expansion of the THV, and paravalvular
regurgitation (PR) were evaluated.
Methods: Transcatheter aortic valve replacement (TAVR) of a SAPIEN XT THV was
performed in 35 patients using standard TEE sizing criteria. The cross-sectional area
and eccentricity of the aortic annulus and implant were determined from matched pre
and post TAVR MDCTs. Eccentricity index (EI) was defined as 1-minimum
diameter/maximum diameter of the pre-TAVR annulus or the post-TAVR THV.
Expansion ratio (ER) was defined as THV area as determined by MDCT/nominal THV
area. Nominal areas for the 23mm and 26mm balloon-expandable valves are 415mm2
and 531mm2 respectively. Implanted valves were deemed ‘over-sized’ when the
nominal THV area was > the annular area and ‘under-sized’ when the nominal THV
area was < the annular area. PR was assessed by TEE.
Results: Annular eccentricity was significantly reduced after TAVR (EI:22.5±7.1%
vs.2.4±1.9%,p<0.001). An eccentric annulus did not correlate with expansion (r=0.08)
or eccentricity of the implanted THV (r=-0.16). Valves were fully expanded in all cases
(mean ER:105.2±5.6%). THVs were undersized in 34.5%(12/35). There was no
difference in post-implant eccentricity or expansion whether the THV was over-sized
or under-sized. (EI:3.2±2.7% vs.1.9±1.1%, p=0.15, ER :107.0±7.4% vs 104.2±4.4%
p=0.23). The THV was undersized in 17.6% of patients with no/trace PR and 53.5%
with mild PAR (p=0.04) and 66.6% with > moderate PR.
Conclusion: An eccentric annulus was not associated with eccentricity or under-
expansion of balloon-expandable THVs. THV under-sizing, as assessed by MDCT
annular area, was associated with increasing PR. Evaluation of the eccentric
dimensions of the aortic annulus may improve THV sizing.
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MitraClip for Patients With Mitral Regurgitation Who are Ineligible for
Surgical Repair or Replacement: A UK Based Cost-Utility Analysis
Stuart Mealing, James N Eaton
Health Economics, Oxford Outcomes, Oxford, United Kingdom
Background: Treatment for individuals with symptomatic severe mitral regurgitation
(SMR) involves a procedure to either repair or replace the mitral valve. However, a
group of patients exist for whom such a procedure is deemed too high risk and who
receive medical management (MM). Prognosis in this patient group is poor. MitraClip
is a minimally invasive intervention for the treatment of SMR and as such may be of
value in this patient group. The economic value of such innovative therapies should
be assessed via the development of a cost-effectiveness model in the relevant patient
group.
Methods: A ten year Markov model was developed in Microsoft Excel®. Treatment
options included were MitraClip and MM. Mortality, adverse events and cross sectional
NYHA data was taken from the EVEREST II High Risk Cohort and concurrent control
group. The composition of MM was assumed to be the same as reported in a relevant
UK health technology assessment and unit costs were taken from appropriate national
databases. Decrements were applied to age-specific EQ-5D population norms to
generate quality adjusted life years (QALYs). Extensive probabilistic and deterministic
sensitivity analyses were undertaken. Costs and benefits were both discounted at 3.5%
p.a.
Results: The base case incremental cost-effectiveness ratio (ICER) was £12,092 per
QALY gained (95% CI £8,889 - £17,388) and £8,584 per life year gained. Treatment
conferred an additional 3.63 years of life compared to MM. At a willingness to pay
threshold of £20,000 per QALY gained, MitraClip had a 99.6% probability of being
cost-effective. Results were not sensitive to changes in the method used to model
baseline mortality, treatment related disutility, utility decrements, heart failure related
hospitalisation rates and long term MitraClip related re-operation. The base case ICER
is in line with those in other positive cardiovascular related appraisals undertaken by
the UK National Institute for Health and Clinical Excellence (NICE)
Conclusion: MitraClip is a cost-effective treatment for patients with SMR who are
currently ineligible for surgical repair or replacement.
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Background: Controversy remains on whether reduction of MR grade to 2+ is
sufficient to provide improvements in clinical measures. This analysis will present
measures of clinical benefit stratified by MR severity at 1 year in a large cohort of high
surgical risk patients.
Methods: EVEREST II high surgical risk patients (n=211) with significant
symptomatic MR with 1 year follow-up are included in this analysis. High surgical
risk was protocol-defined as STS predicted or surgeon estimated operative mortality
of ≥ 12%. Clinical benefit was measured by LV volumes, NYHA Class and Quality of
Life scores and will be stratified based on MR severity at 1 year (≤ 1+ vs. 2+).
Results: A majority of high surgical risk patients had functional MR (71%), prior
cardiac surgery (58%), and AF (64%). Mean predicted surgical mortality using the
STS calculator was 12.2 ± 7.9%. Through 1 year, 50 patients died and 8 withdrew. Of
the remaining patients with matched echocardiograms at baseline and 1 year (n=123),
82% achieved MR ≤ 2+ (36% with MR <=1+, n=44 and 46% with 2+ MR, n=57).
Significant improvements in LV function, NYHA Class and QOL were observed with
both 1+ and 2+ MR at 1 year (Table).
Conclusion: MitraClip therapy significantly reduced LV size and improved NYHA
Class and quality of life at 1 year regardless of residual MR (≤ 1+ vs 2+) in these high
surgical risk patients. The MitraClip procedure is an important therapeutic option for
select patients with significant MR at high risk of surgical mortality.
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Valvuloplasty: a Simple Predictor of Restenosis at Long-Term Follow Up
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Background: Objective: to investigate the factors associated with restenosis (RS) after
successful percutaneous mitral valvuloplasty (PMV).
Methods: 132 patients (pts) who underwent PMV with Inoue balloon catheter were
consecutively included. Successful results were defined as post-procedure mitral valve
area (MVA) ≥ 1.5 cm2 as assessed by echocardiography and mitral regurgitation (MR)
<3/4 grade (Sellers classification).Pts were clinical and echocardiographicaly evaluated
immediately after procedure, 6 months after and once per year thereafter, evaluating
Wilkins echocardiographic score (ES), mitral valve area (MVA), pulmonary artery
systolic pressure (PAPs) and mitral regurgitation (MR). Following endpoints were
considered: restenosis (RS), mitral valve replacement (MVR),new PMV requirement
or death.A univariate and multivariate analysis were used to determine independent
predictors for outcome. To assess the cut-off point of immediate post-PMV MVA for
predicting restenosis 5 years after successful PMV, receiver-operating characteristic
(ROC) curves were used; the optimal cut-off value was defined as the value with the
maximal sum of sensitivity and specificity. A value of p <0.05 was considered
significant.
Results: Median follow-up was 48 months (Q25-75: 24-84). The mean age was
44.2±13 years,115 pts were women. The median ES was 7; 28.3% of pts had ES> 8.
There were 30.3% of pts with atrial fibrillation(AF).The median MVA before the
procedure was 0.90 cm2; the PMV inmediate success was 78.8%.The median post-
PMV MVA was 1.71 cm2. Long term outcomes are shown in table 1. The best
immediate post-PMV MVA cut-off value for predicting RS was 1.8 cm2 (95%CI:1.5-
1.9).There were 3 in-hospital deaths and 3 deaths at follow-up. ES>8(p=0.04) and
postPMV MVA <1.8 cm2 (p =0.02) were associated with RS at 60 months follow-
up.After multivariate analysis, the only variable associated with RS at follow up was
post-PMV MVA < 1.8 cm2(OR:2.6,95%CI:6.2-1.1)
Table 1.
Conclusion: Inmediate post-PMV MVA < 1.8 cm2 was an important predictor of
restenosis and this value should be considered as a component of optimal result.
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